Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals for AS include improving signs and symptoms of the disease, improving physical function, preventing disability, and slowing or preventing structural damage. TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia, and infliximab biosimilars) have demonstrated efficacy in reducing disease activity in AS. All approved agents in this class are perceived as highly effective options for patients who require more-potent therapies beyond first-line nonsteroidal anti-inflammatory drugs (NSAIDs). Novartis’s IL-17 inhibitor Cosentyx offers an alternative mechanism of action as the only approved non-TNF biological therapy for AS.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key drugs: Humira, Enbrel, Remicade, Simponi, Cimzia, Cosentyx, Vimovo, methotrexate.